CEO Krish Krishnan highlighted 2024 as a strong year, driven by the continued success of the VYJUVEK launch in the U.S., which is tracking as a top-tier rare disease launch. He emphasized the ...
Trinity Biotech plc announced that it has achieved Adjusted EBITDA-positive operations during Q2 2025 and expects to maintain this positive trajectory going forward, marking a key milestone in its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback